LASN500 / Lassen Therap - LARVOL DELTA

LASN500, an anti-IL18BP therapeutic antibody, has the potential to overcome anti-PD-1 resistant disease (SITC 2024) - "Analysis of tumor lysates confirmed increases in T cell and cytokine levels that correlated with efficacy. These data suggest that LASN500, a potent antibody to human IL-18BP, has the potential to enhance immune response in both anti-PD-1 sensitive and resistant patient disease by expanding T-cell populations in the tumor microenvironment."

IO biomarker • Oncology • IFNG • IL18 • IL18BP

Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects. (PubMed, Cancer Immunol Res) - "To restore the activity of endogenous IL18, we generated COM503, a high-affinity anti-IL18BP that blocks the IL18BP:IL18 interaction and displaces precomplexed IL18, thereby enhancing T- and NK-cell activation. In contrast, no increase in inflammatory cytokines and lymphocyte numbers or activation state was observed in serum and spleen. Taken together, blocking IL18BP using an Ab is a promising approach to harness cytokine biology for the treatment of cancer."

Journal • Immune Modulation • Immunology • Oncology • IFNG • IL18BP

Discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity (SITC 2023) - "Additionally, we observe an increase in NK cells and granzyme B expression in response to combination therapy. Conclusions These data suggest that inhibition of IL-18/IL-18BP binding may prove efficacious in the treatment of cancers where IL-18BP prevents an IL-18-mediated proinflammatory response."

IO biomarker • Oncology • GZMB • IFNG • IL18 • IL18BP

Lassen Therapeutics Presents Data Demonstrating Anti-IL18 Binding Protein Antibody Efficacy and Enhancement of Anti-Tumor Immunity at AACR Annual Meeting (Businesswire) - "Lassen Therapeutics...will present new preclinical data demonstrating activity of its anti-interleukin-18 binding protein (IL-18BP) antibody and efficacy in combination with anti-PD-1 at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held in Orlando, Florida....Lassen’s anti-IL18BP antibodies demonstrated anti-tumor efficacy in a mouse syngeneic tumor model in combination with IL-18, anti-PD-1, and anti-PD-1 plus IL-18. The antibodies have been shown to induce potent stimulation of interferon gamma and other proinflammatory cytokines and chemokines in vitro and in vivo."

Preclinical • Oncology